IMO
Nothing wrong here - normal biotech business
CR's are always a constant with biotechs - hitting the market constantly for cash is nothing new in this game
The 30 patient data does not imo seem strong enough to merit a CR at well above market
Capital raises between inflection points only benefits a select few
Newbies note - we were told that no cash required until 1st Half 2021 - unreal and misleading statements. imo
DYOR
- Forums
- ASX - By Stock
- Question for James Garner/CC
IMONothing wrong here - normal biotech business CR's are always...
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online